8247 — BioSino Bio-technology and Science Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Market Cap
HK$149.05m
Enterprise Value
HK$258.97m
Revenue
CNY263.07m

Annual income statement for BioSino Bio-technology and Science, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	HKAS	HKAS	HKAS	HKAS	HKAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	325	348	373	289	263
Cost of Revenue
Gross Profit	111	144	146	127	108
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	314	333	354	313	313
Operating Profit	11.3	15.4	18.8	-23.6	-50
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	2.15	6.41	18.5	-17.6	-59.7
Provision for Income Taxes
Net Income After Taxes	-0.706	3.16	14.2	-19.2	-56.9
Minority Interest
Net Income Before Extraordinary Items
Net Income	2.72	-1.14	8.11	-11.6	-42.5
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2.72	-1.14	8.11	-11.6	-42.5
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.021	-0.005	0.06	-0.078	-0.219
Dividends per Share